SPC
MDNA

Sigma Planning Corp’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Sigma Planning Corp’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-634,550
Closed -$187K – 1221
2023
Q3 		$187K Buy
634,550
+329,250
+108% +$128K 0.01% 1102
2023
Q2 		$147K Buy
305,300
+3,250
+1% +$2.01K 0.01% 1129
2023
Q1 		$190K Sell
302,050
-500
-0.2% -$312 0.01% 1183
2022
Q4 		$139K Buy
302,550
+39,500
+15% +$24.1K 0.01% 1170
2022
Q3 		$218K Buy
263,050
+11,000
+4% +$12.4K 0.01% 1085
2022
Q2 		$292K Buy
252,050
+51,750
+26% +$55.3K 0.01% 1004
2022
Q1 		$256K Buy
200,300
+60,250
+43% +$93.6K 0.01% 1140
2021
Q4 		$228K Buy
140,050
+109,550
+359% +$227K 0.01% 1221
2021
Q3 		$84K Buy
+30,500
New +$75.6K ﹤0.01% 1325

Other funds holding MDNA

RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
NDSI
Newman Dignan & Sheerar Inc Providence, Rhode Island $523M AUM 26.16% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Sigma Planning Corp's MDNA Position: Q4 2023 in Review

Sigma Planning Corp sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q4 2023, closing a stake of 634,550 shares — an estimated $187K sold.

Sigma Planning Corp first reported a position in MDNA in Q3 2021 and held it in 9 quarters. The position peaked at $292K in Q2 2022. 3 funds tracked by Wall St. Rank hold MDNA as of Q4 2023.

  • Sigma Planning Corp reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q4 2023 after selling out during the quarter.
  • Sigma Planning Corp sold 634,550 Medicenna Therapeutics Corp. Common Shares shares in Q4 2023, an estimated $187K.
  • Sigma Planning Corp first reported a position in Medicenna Therapeutics Corp. Common Shares in Q3 2021 and held it in 9 quarters.
  • Sigma Planning Corp's Medicenna Therapeutics Corp. Common Shares position peaked at $292K in Q2 2022.
  • 3 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q4 2023.

Based on Sigma Planning Corp's 13F filing for Q4 2023, filed 1 Feb 2024.